Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 222 participants.

Also called NCT01326026

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 222 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01326026
  • EudraCT 2010-022337-29
Other papers using this trial's data
  • Insulin degludec once-daily in type 2 diabetes: simple or step-wise titration (BEGIN: once simple use) Advances in therapy, 2013-06 DOI, PubMed 23812875, PMC3730088 In the PMC Open Access subset under a licence that is not Creative Commons.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Finland, Germany, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01326026. Randomized; no masking; primary purpose treatment. Start 2011-03 (registry gives no type); primary completion 2011-12 (actual). Results posted on 2015-11-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus
Acronym
BEGIN™
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
insulin degludec
Intervention (Drug)
insulin degludec
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct01326026
Content hash
cedb7a0222f1cb192ed5daa8c5c7a836735194f179ead9f01b86e07e37394f16